Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8445524 | CEPHALON | Solid forms of bendamustine hydrochloride |
Mar, 2029
(4 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8895756 | CEPHALON | Bendamustine pharmaceutical compositions |
Jan, 2026
(1 year, 8 months from now) | |
US8609863 | CEPHALON | Bendamustine pharmaceutical compositions |
Jan, 2026
(1 year, 8 months from now) | |
US8791270 | CEPHALON | Bendamustine pharmaceutical compositions |
Jan, 2026
(1 year, 8 months from now) | |
US8791270 (Pediatric) | CEPHALON | Bendamustine pharmaceutical compositions |
Jul, 2026
(2 years from now) | |
US8609863 (Pediatric) | CEPHALON | Bendamustine pharmaceutical compositions |
Jul, 2026
(2 years from now) | |
US8895756 (Pediatric) | CEPHALON | Bendamustine pharmaceutical compositions |
Jul, 2026
(2 years from now) | |
US9533955 | CEPHALON | Solid forms of bendamustine hydrochloride |
Mar, 2029
(4 years from now) | |
US8883836 | CEPHALON | Solid forms of bendamustine hydrochloride |
Mar, 2029
(4 years from now) | |
US8669279 | CEPHALON | Solid forms of bendamustine hydrochloride |
Mar, 2029
(4 years from now) | |
US8344006 | CEPHALON | Liquid formulations of bendamustine |
Sep, 2029
(5 years from now) | |
US8883836 (Pediatric) | CEPHALON | Solid forms of bendamustine hydrochloride |
Sep, 2029
(5 years from now) | |
US8669279 (Pediatric) | CEPHALON | Solid forms of bendamustine hydrochloride |
Sep, 2029
(5 years from now) | |
US8445524 (Pediatric) | CEPHALON | Solid forms of bendamustine hydrochloride |
Sep, 2029
(5 years from now) | |
US9533955 (Pediatric) | CEPHALON | Solid forms of bendamustine hydrochloride |
Sep, 2029
(5 years from now) | |
US8344006 (Pediatric) | CEPHALON | Liquid formulations of bendamustine |
Mar, 2030
(5 years from now) | |
US8436190 | CEPHALON | Bendamustine pharmaceutical compositions |
Oct, 2030
(6 years from now) | |
US8436190 (Pediatric) | CEPHALON | Bendamustine pharmaceutical compositions |
Apr, 2031
(6 years from now) |
Treanda is owned by Cephalon.
Treanda contains Bendamustine Hydrochloride.
Treanda has a total of 18 drug patents out of which 0 drug patents have expired.
Treanda was authorised for market use on 01 May, 2009.
Treanda is available in powder;iv (infusion), solution;iv (infusion) dosage forms.
Treanda can be used as for use in the treatment of patients with chronic lymphocytic leukemia (cll) and/or indolent b-cell non-hodgkin lymphoma (nhl), for use in the treatment of patients with chronic lymphocytic leukemia (cll), for use in the treatment of patients with chronic lymphocytic leukemia and/or non-hodgkins lymphoma.
Drug patent challenges can be filed against Treanda from 02 May, 2015.
The generics of Treanda are possible to be released after 26 April, 2031.
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Indication(I-580) | Oct 31, 2011 |
Orphan Drug Exclusivity(ODE) | Mar 20, 2015 |
Pediatric Exclusivity(PED) | Sep 20, 2013 |
ODE*(ODE*) | Dec 07, 2022 |
New Chemical Entity Exclusivity(NCE) | Mar 20, 2013 |
Drugs and Companies using BENDAMUSTINE HYDROCHLORIDE ingredient
NCE-1 date: 02 May, 2015
Market Authorisation Date: 01 May, 2009
Treatment: For use in the treatment of patients with chronic lymphocytic leukemia and/or non-hodgkins lymphoma; For use in the treatment of patients with chronic lymphocytic leukemia (cll); For use in the treatm...
Dosage: POWDER;IV (INFUSION); SOLUTION;IV (INFUSION)